This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

cpm/mg tissue

PG release (ug/mg)

Figure 1




Figure 2






Figure 3










Figure 6




337DIPEN**FFGVG**......368 NITEGEARGSV


Figure 7

ffect of interleukins on MMPs



Induction of MMPs in chondrocytes








Figure 10




FIG. 11





FIG. 12

fect of anti-IL-17 in an RA model






FIG. 14




FIG. 15

IL 17 increases basal and IL-1%-induced nitric oxide release




FIG. 16

Inhibition of naric oxide release does not block the detrimental effects of 11. 17 on matrix breakdown or synthesis




FIG. 17

L-NIO

INHIBITION Of NO release enhances IL1-4-induced matrix breakdown but not matrix synthesis




FIG. 18